/
AVTX
$19.45-$0.10 (-0.51%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.0B
54M shares
52-week range
$8.41 – $24.27
70% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-8274.95
Avalo Therapeutics, Inc. Common Stock
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
www.avalotx.com- Employees
- 33
- IPO / List date
- Nov 13, 2015
- HQ
- WAYNE, PA
Held by traders on TradeandTell
No one on the platform currently holds AVTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 120,114 | $1.8M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-12-29 | 1-for-240reverse |
| 2022-07-08 | 1-for-12reverse |
| 2007-09-10 | 1-for-51reverse |
Recent trades on TradeandTell
No one on the platform has traded AVTX yet.
